Medical/Pharmaceuticals
2022 Japan Prize Laureates Announced
TOKYO, Jan. 25, 2022 /PRNewswire/ -- The Japan Prize Foundation announced the winners of the 2022 Japan prize onJanuary 25. Prof. Katalin Kariko (Hungary/USA ) and Prof.Drew Weissman (USA) are co-winners of the Japan Prize in the field of "Materials and Production," and Prof.Christopher Field (USA...
2022-01-25 14:00
2161
RemeGen's Telitacicept Demonstrates Positive Results in Phase II Trial in Treatment of Primary Sjögren's Syndrome
YANTAI, China, Jan. 24, 2022 /PRNewswire/ -- RemeGen Co., Ltd. (9995.HK), a commercial-ready biotechnology company, recently announced positive results from the completion of its Phase II trial inChina for Telitacicept in the treatment of primary Sjögren's syndrome ("pSS"). A total of 42 patient...
2022-01-25 09:00
3894
ImmVira's New-Generation Vector Poised to Enable CAR-T Treatment for Solid Tumors
SHENZHEN, China, Jan. 24, 2022 /PRNewswire/ -- Demonstrating innovation leadership on a global level, ImmVira announced that, its custom-designed new-generation oncolytic herpes simplex virus ("oHSV") vector enabling CAR-T treatment for solid tumors has started pilot-scale manufacturing and Phar...
2022-01-25 08:30
1922
Kintor Pharma Announced Successful Dosing of the First Patient for Acne Vulgaris Phase II Clinical Trial of KX-826
SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the first patient dosing in its phase II clinical trial of KX-826("p...
2022-01-24 21:47
3015
MGI's New MGISP-Smart 8 Automated Sample Preparation System Makes International Debut at MEDLAB Middle East
DUBAI, UAE, Jan. 24, 2022 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a global life science leader and innovator, has unveiled its new MGISP-Smart 8 automated sample preparation system to the world at MEDLAB Middle East, which kicked off today at the Dubai World Trade Center. The event marks the ...
2022-01-24 19:30
1884
Samsung Biologics Reports Fourth Quarter & Fiscal Year 2021 Financial Results
* Q4'21 revenue of KRW 444.3 billion increased 18% compared to Q4'20. * Q4'21 operating profit of KRW 128.8 billion increased 39% compared to Q4'20. * FY'21 revenue of KRW 1,568.0 billion, an increase of 35% compared to FY'20. * FY'21 operating profit of KRW 537.3 billion, an increase of 84% ...
2022-01-24 16:25
2631
Harbour BioMed Announces Dosing of First Patient in Combination Therapy Phase Ib/IIa Trial of Next-Generation Anti-CTLA-4 Antibody
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that, it has successfully completed the dosing of first patient in phase Ib/IIa trial at the stage of dose expansion of its anti-CTLA-4 antibody (HBM4003) in ...
2022-01-24 15:39
2149
ELEVAI LABS, INC. ANNOUNCES GLOBAL DISTRIBUTION PARTNERSHIP WITH PREMIER AESTHETIC DEVICE COMPANY DERMAPENWORLD
DAVIS, Calif., Jan. 21, 2022 /PRNewswire/ -- ELEVAI LABS, INC., ("ELEVAI" or the "Company") a biotech company leveraging the power of human stem cell exosomes to create next-generation topical skincare products, is pleased to announce that it has signed a non-exclusive global distributor and trad...
2022-01-21 13:41
2003
HanAll Biopharma Reports Full-Year 2021 Results and Provides Business Update
* 2021 sales of KRW 101.6 billion for a 15% increase from 2020 * 2021 operating profit of KRW 10.1 billion grew by 70% from 2020 * Increasing milestone payments and revenues from R&D activities are reinvested into new R&D programs SEOUL, South Korea, Jan. 20, 2022 /PRNewswire/ -- [Busines...
2022-01-20 22:00
2606
Volition presents study data at ASCO GI 2022 on circulating nucleosomes for the detection of colorectal cancer and high-risk advanced adenomas
AUSTIN, Texas, Jan. 20, 2022 /PRNewswire/ --VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced the results of two large scale clinical studies, which show that the company's Nu.Q® assays, when used in conjunction with the Fecal Immunochemica...
2022-01-20 21:30
3945
Hinova Announces First Patient Dosed in a Phase I Clinical Trial of HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment
MELBOURNE, Australia, Jan. 20, 2022 /PRNewswire/ -- Hinova Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cancers and metabolic diseases through targeted protein degradation technologies, today announced that the first patient with m...
2022-01-20 20:28
2282
Senhwa's Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Biliary Tract Cancer
TAIPEI and SAN DIEGO, Jan. 20, 2022 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Des...
2022-01-20 20:00
2626
Nippon Express (Belgium) Acquires GDP Certification for Facility in Brussels Airport's Cargo Area
TOKYO, Jan. 20, 2022 /PRNewswire/ -- Nippon Express (Belgium) N.V./S.A. (hereinafter "NX Belgium"), a company of the Nippon Express Holdings, Inc. Group, has obtained Good Distribution Practice (GDP) certification, effective December 21, 2021, for air and ground forwarding operations, inclusive of...
2022-01-20 15:00
1989
GORE® CARDIOFORM Septal Occluder Marks 10 Years of Improving Lives
After a decade of clinical use* and more than 50,000 devices sold globally, the GORE® CARDIOFORM Septal Occluder continues a trusted legacy of safely advancing care. FLAGSTAFF, Ariz., Jan. 20, 2022 /PRNewswire/ -- W. L. Gore & Associates (Gore) today announced that the GORE® CARDIOFORM Septal Oc...
2022-01-20 10:17
2483
Australia Therapeutic Goods Administration (TGA) Grants Provisional Registration for Novavax COVID-19 Vaccine
Nuvaxovid™ is the first protein-based COVID-19 vaccine to receive approval for provisional registration inAustralia GAITHERSBURG, Md., Jan. 20, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for seri...
2022-01-20 07:29
1764
Neurophth Therapeutics Receives IND Clearance to Initiate Clinical Trial for China AAV-ND4 Gene Therapy NR082 in Leber Hereditary Optic Neuropathy
WUHAN, China and SAN DIEGO, Jan. 19, 2022 /PRNewswire/ -- Neurophth Therapeutics, Inc., (hereinafter referred to as "Neurophth"), today announced receiving the U.S. Food and Drug Administration (FDA) clearance of its investigational new drug (IND) application on thein-vivo gene replacement thera...
2022-01-19 22:30
2185
Qilian International Holding Group Limited Receives Approval for the Sale of its Newly Developed Nitrofurantoin Enteric-coated Tablets
JIUQUAN, China, Jan. 19, 2022 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company", "Qilian International", "we", "our" or "us"), aChina-based pharmaceutical and chemical products manufacturer, today announced that the Company received approval from Gansu Provin...
2022-01-19 20:30
2141
Peijia Medical Obtained Exclusive License for JenaValve's Trilogy TAVR System for Treating AR in the Greater China Region
SUZHOU, China, Jan. 19, 2022 /PRNewswire/ -- Peijia Medical Limited (HKEX: 9996) is pleased to announce its strategic investment and exclusive in-licensing agreement with JenaValve Technology, Inc. Under the terms of the agreement, Peijia has made a cash and equity investment in JenaValve and wil...
2022-01-19 20:00
4097
Eluminex Biosciences Acquires Zuretinol Acetate from Retinagenix Holdings
* Purchase of Assets and Related Global Commercialization Rights for Oral 9- cis-Retinol (Zuretinol) for Rare Forms of Childhood Blindness. * Clinical Stage Asset Has Potential for First Approved Oral Therapy for Leber's Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP) Caused by Mutati...
2022-01-19 19:49
1995
ImmVira's MVR-T3011 IV completed first 2 cohorts dose-escalation of U.S. Phase I clinical study with favorable safety data
SHENZHEN, China, Jan. 18, 2022 /PRNewswire/ -- ImmVira's breakthrough product MVR-T3011 IV, global first clinical-stage oncolytic herpes simplex virus (oHSV) via intravenous injection, has recently completed first 2 cohorts dose-escalation of U.S. Phase I clinical study, and demonstrated good saf...
2022-01-19 08:30
1814
Week's Top Stories
Most Reposted
Agoda Launches Free Global eSIMs for VIP Diamond Members
[Picked up by 322 media titles]
2026-02-10 14:00
DBS is First Bank in Asia Pacific to Pilot Visa Intelligent Commerce for Everyday Payments
[Picked up by 320 media titles]
2026-02-16 10:00
Ascentium Acquires Clara, Expanding into the Abu Dhabi Global Market (ADGM) and Strengthening its Middle East Presence
[Picked up by 310 media titles]
2026-02-12 14:00
Blackpanda Japan Announces Strategic Partnership with SoftBank to Strengthen Cyber Incident Response in Japan
[Picked up by 298 media titles]
2026-02-10 13:31Carro unveils quirky generative AI ad campaign highlighting its 'Surprisingly Short' AI-enabled car-selling process
[Picked up by 296 media titles]
2026-02-11 11:00
Most Read
Agoda Launches Free Global eSIMs for VIP Diamond Members
2026-02-10 14:00
6360
eufy Raises the Bar for Home Cleaning with Omni C28, Delivering One-Pass-Clean Performance with HydroJet™ Self-Clean Roller Mop
2026-02-14 10:00
6269
Datasea Reports Second Fiscal Quarter 2026 Results
2026-02-12 22:20
5868